Kawasaki disease with dilatation of the common bile duct: A case report and review of literature

Atsushi Morita1 | Kazuo Imagawa1,2 | Takumi Ishiodori1 | Manabu Tagawa1,2 | Hidetoshi Takada1,2

1Department of Pediatrics, University of Tsukuba Hospital, Tsukuba, Japan
2Department of Child Health, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

Correspondence
Kazuo Imagawa, Department of Pediatrics, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba, Ibaraki 305-8578, Japan. Email: imagawa-tuk@md.tsukuba.ac.jp

Abstract

Background: Kawasaki disease (KD) is a syndrome that results in acute systemic vasculitis and is a major cause of acquired heart disease in developed countries. KD is diagnosed based on certain characteristic symptoms and echocardiogram results. It has been reported that abdominal ultrasound is of value in supporting the diagnosis of KD. Nevertheless, abdominal ultrasound is not a routine procedure in KD. Moreover, dilatation of the common bile duct (CBD) has been rarely reported in previous cases.

Case presentation: A 4-year-old boy presented with fever and markedly high transaminase level (aspartate aminotransferase, 5323 U/L; alanine aminotransferase, 1554 U/L). The patient was diagnosed as having KD based on characteristic symptoms and echocardiogram findings. Ultrasound revealed dilatation of the CBD as well as cervical lymphadenopathy resembling a cluster of grapes, thickening of the gallbladder wall, and increased periportal echogenicity throughout the liver parenchyma. The patient received initial treatment with intravenous immunoglobulin at day 4 of fever and second-line treatment with intravenous immunoglobulin and prednisolone because of recurrent fever on day 6. Dilatation of the CBD was improved from 6.6 mm on day 4 to 3.1 mm on day 8. Although re-dilatation was observed, it gradually diminished and normalized (4.3 mm on day 28, 4.0 mm on day 63, 3.3 mm on day 105, and 2.8 mm on day 182).

Conclusion: This case highlights the usefulness of abdominal ultrasound and the importance of considering dilatation of the CBD as one of the complications of KD.

KEYWORDS
abdominal ultrasound, cholangitis, cholecystitis, cytokine, hepatobiliary abnormalities, interleukin-6, ultrasonography

1 | INTRODUCTION

Kawasaki disease (KD) is a syndrome that results in acute systemic vasculitis, affecting mainly infants and children, and is a major cause of acquired heart disease in developed countries.1 Although KD was first described by Tomisaku Kawasaki in 1967,2-4 the cause of the disease is still unknown. Therefore, to date, KD is diagnosed based on certain characteristic symptoms and echocardiogram results.5

It has been reported that neck and abdominal ultrasound is of value in supporting the diagnosis of KD; for instance, characteristics such as cervical lymphadenopathy resembling a cluster of grapes,6 severe dilatation of the gallbladder—called hydrops of the...
gallbladder, thickening of gallbladder wall, and segmental bowel-wall thickening support the diagnosis of KD. Nevertheless, abdominal ultrasound is not a routine procedure in KD. Moreover, dilatation of the common bile duct (CBD) has been rarely reported.

Herein, we report the case of a 4-year-old boy with KD, and with various ultrasound findings including dilatation of the CBD during the acute phase of the disease.

2 | CASE PRESENTATION

A 4-year-old boy was admitted to our hospital because of markedly high levels of transaminase. The patient had been well until 3 days before admission, when a runny nose and fever were noted. On the day of symptom onset, the patient was evaluated by his primary-care pediatrician and was diagnosed as having bronchitis. After which, the patient experienced nausea and vomiting and was taken to the emergency department at another hospital. At the other hospital, the patient did not appear ill but had redness in the pharynx and cervical lymphadenopathy. The blood test results showed high transaminase levels, after which he was transferred to our hospital.

On arrival, the patient appeared ill and was febrile, with a body temperature of 40.4°C. His blood pressure was 97/48 mm Hg, pulse rate was 148 beats per minute, respiratory rate was 28 breaths per minute, with oxygen saturation of 96% while breathing ambient air. Physical examination revealed bilateral conjunctival congestion, erythema around the navel, reddening and indurative edema of palms, and cervical lymphadenopathy. There was no evidence of reddening of the lips, strawberry tongue, and redness at the site of bacille Calmette-Guérin inoculation. The blood test results showed markedly high level of transaminase with acute inflammatory response (white blood cell count, 16 400/µL; erythrocyte sedimentation rate, 50 mm/h; C-reactive protein, 157 mg/L; aspartate aminotransferase, 5323 U/L; alanine aminotransferase, 1554 U/L; total bilirubin, 1.5 mg/dL; γ-glutamyl transpeptidase, 149 U/L; and total bile acid, 381.1 µmol/L). There was no evidence of viral hepatitis (negative results of hepatitis A virus antibody, hepatitis B surface antigen, hepatitis C virus antibody, and polymerase chain reaction for Epstein-Barr virus, cytomegalovirus, herpes simplex viruses 1 and 2, and human herpes virus 6) or autoimmune hepatitis. No bacterial growth was detected in any of the cultures. Some cytokines were measured using cytokine bead assay (BD™ CBA kit, Becton Dickinson, Franklin Lakes, NJ, USA); interleukin-6 (IL-6) level increased to 87.7 pg/mL (reference value <7.0 pg/mL), IL-10 increased to 32.0 pg/mL (reference value <5.0 pg/mL), whereas IL-1β and tumor necrosis factor-α levels were normal. Although the echocardiogram showed normal cardiac function with no evidence of valve regurgitation, slight dilatation of the left main trunk was observed (Figure 1). Ultrasonographic evaluation of cervical lymph nodes revealed multiple hypoechoic-enlarged nodes, which resembled a cluster of grapes (Figure 2A).

An abdominal ultrasound showed thickening of the gallbladder wall, increased periportal echogenicity throughout the liver parenchyma, and dilatation of the CBD with a maximum diameter of 6.6 mm at the intrapancreatic region (4-year-old standard value, 2.3 mm, upper limit, 3.7 mm) (Figure 2B-D). No evidence of biliary calculus and pancreatitis was observed.

After admission, intravenous administration of cefotaxime was initiated; however, it was ineffective. On the next day of hospitalization (day 4 of fever), reddening of lips was observed and the patient was diagnosed with KD based on the presence of five principal symptoms. Intravenous immunoglobulin (2 g/kg) was administered as initial therapy. Oral aspirin was not administered because of the high transaminase level. A Kobayashi score of 8 suggested that the patient was at high risk of intravenous immunoglobulin resistance. Viral hepatitis could not be completely ruled out at this point; therefore, steroid administration was avoided. The patient’s fever rapidly decreased with the initiation of treatment, and transaminase level gradually improved. However, the patient’s fever relapsed on day 6, so intravenous immunoglobulin (2 g/kg) and intravenous prednisolone (2 mg/kg/day) were administered as second-line therapy. Flurbiprofen, which is used as an alternative to oral aspirin in Japan when high transaminase levels are observed, was also administered.
because the transaminase level remained high (aspartate aminotransferase, 171 IU/L; alanine aminotransferase, 468 IU/L). The patient maintained a defervesced state after second-line therapy. Oral medication was switched from flurbiprofen to oral aspirin (5 mg/kg/day) on day 10 (aspartate aminotransferase, 45 IU/L; alanine aminotransferase, 171 IU/L), and prednisolone administration was simultaneously changed from intravenous to oral because the patient’s C-reactive protein level normalized. Following which, prednisolone administration was tapered in 5-day steps—from 2 mg/kg/day to 1 mg/kg/day to 0.5 mg/kg/day. Membranous desquamation appeared on the fingertips on day 15.

The maximum diameter of the CBD reduced from 6.6 mm on day 4 to 3.1 mm on day 8. Although re-dilatation was observed, it gradually diminished and normalized (4.3 mm on day 28, 4.0 mm on day 63, 3.3 mm on day 105, and 2.8 mm on day 182). The thickening of the gallbladder wall was persistent on day 8; however, it improved after day 28. All abdominal ultrasound tests were performed in a fasting state (Figure 2D). No exacerbation of coronary lesions was observed.

**Figure 2** Neck and abdominal ultrasound and shift of maximum diameter of the common bile duct, performed on day 4. Neck ultrasound showed multiple hypoechoic-enlarged nodes which resembled a cluster of grapes (A). Abdominal ultrasound showed increased periportal echogenicity throughout the liver parenchyma (B), dilatation of common bile duct (C, D) and thickening of gallbladder wall (D). The maximum diameter of the common bile duct shifted as follows: day 4: 6.6 mm, day 8: 3.1 mm, day 28: 4.3 mm, day 63: 4.0 mm, day 105: 3.3 mm, and day 182: 2.8 mm (4-year-old standard value is 2.3 mm, upper limit is 3.7 mm). All tests were performed in a fasting state. Thickening of the gallbladder wall remained on day 8, but it improved after day 28. Abbreviations: CBD, common bile duct; GB, gallbladder; SMV, superior mesenteric vein; TP, transverse portion of the portal vein; UP, umbilical portion of the portal vein.
3 | DISCUSSION

Our patient was diagnosed with acute KD and showed dilatation of the CBD. Very few reports are available on biliary dilatation in KD patients (Table 1). To the best of our knowledge, only one Japanese study has previously reported on a case of acute-phase KD (only available in the Japanese literature),13 and our case is the first of its kind to be reported in an international journal.

A Japanese report evaluated the hepatobiliary system using abdominal ultrasound in 68 patients with KD every 3 or 4 days.13 Of the 68 patients, 20 had dilatation of the gallbladder, and among them, four patients had thickening of the gallbladder wall and three had dilatation of the CBD in acute phase. All three patients with dilatation of the CBD had high transaminase level and cholestasis. Dilatation of the CBD regressed spontaneously in 2 weeks to 1 month (Table 1, cases A1-A3). In the present case, the peak value of alanine aminotransferase and the maximum diameter of the CBD were most severe, and took longer to normalize.

In the subacute phase, which is also rare, a total of three cases of biliary dilatation have been reported.14,15 Petersen et al14 reported on a 10-year-old with painless jaundice and elevated amylase level, along with dilatation of the CBD and hydrops of the gallbladder. On endoscopic retrograde cholangiopancreatography, the patient had string-like stenosis in the pre-papillary CBD (Table 1, case S1). Cherry et al reported two cases; one was of a 6-year-old boy who experienced recurrent abdominal pain, jaundice, and persistent elevation of transaminases with dilatation of the CBD. On computed tomography, the patient had CBD stenosis at the level of the pancreatic head (Table 1, case S2). The other case was of a 3-year-old boy who developed pancreatitis. On magnetic resonance cholangiopancreatography, the patient had dilatation of the CBD with tapering near the ampulla of Vater, consistent with stenosis (Table 1, case S3).15 One of the three cases underwent CBD stent placement, the others spontaneously improved.

It is not described whether dilatation of the CBD in the subacute phase was also present in the acute phase. Although abdominal ultrasound as well as computed tomography, magnetic resonance cholangiopancreatography, and endoscopic retrograde cholangiopancreatography are not routine procedures for KD, past cases along with the present case suggest that the presentation of the CBD dilatation in KD may be quite latent if not investigated thoroughly.

Our patient also showed increased levels of transaminase and \( \gamma \)-glutamyl transpeptidase with thickening of the gallbladder wall, increased periporal echogenicity throughout the liver parenchyma, along with dilatation of the CBD detected by abdominal ultrasound, which suggested cholecystitis and intrahepatic/extrahepatic cholangitis. Although there have been few pathological investigations that consider hepatobiliary abnormalities in KD, it has been reported that patients with dilatation of the gallbladder and thickening of the gallbladder wall showed neutrophil infiltration around the gallbladder wall, cystic duct mucosa, and bile duct epithelial cells.16,17 Actually, 62.7% of patients with acute phase KD show an increased \( \gamma \)-glutamyl transpeptidase level and 40.3% show an increase in alanine aminotransferase level.18 These findings indicate that KD may lead to cholecystitis and intrahepatic/extrahepatic cholangitis. The relationship between these pathological conditions and ultrasound findings remains unclear. However, it is presumed that inflammation of the cystic duct results in obstruction, causing hydrops of the gallbladder.13 In addition, our case suggests that thickening of the gallbladder wall, increased periporal echogenicity throughout the liver parenchyma, and dilatation of the CBD also relate to inflammation and subsequent edema and obstruction at each location (Figure 3).

Our patient demonstrated IL-6 elevation detected using a cytokine bead assay (BD™ CBA kit). Interleukin-6 was discovered as a hepatocyte-stimulating factor 2 induced in acute liver inflammation.19 It reduces gene expression of excretory transporters such as

| TABLE 1 | Cases of CBD dilatation in Kawasaki disease |
|---------|------------------------------------------|
| Case    | Age (year) | Period of dilatation (day) | Peak value (ALT (U/mL) | GGT (U/mL) | T-Bil (mg/dL) | D-Bil (mg/dL) | Maximum diameter of CBD (mm) | Reference |
|---------|------------|----------------------------|------------------------|------------|--------------|--------------|-----------------------------|-----------|
| Cases of dilatation of CBD in acute phase | | | | | | | | |
| A1      | 5          | 9-33                      | 120                    | 46         | 2.5          | 1.7          | 5.0                         | 13        |
| A2      | 3          | 6-30                      | 226                    | 220        | 6.7          | 6.2          | 3.0                         | 13        |
| A3      | 2          | 6-14                      | 348                    | 109        | 5.2          | 4.5          | 3.0                         | 13        |
| A4      | 4          | 4-63                      | 1554                   | 149        | 1.5          | 0.9          | 6.6                         | Present case |
| Cases of dilatation of CBD in subacute phase | | | | | | | | |
| S1      | 10         | 19-67                     | n/a                    | n/a        | 8.7          | n/a          | n/a                         | 14        |
| S2      | 6          | 37-97\(^a\)              | 601                    | 364        | 8.7          | 6.3          | 9.0                         | 15        |
| S3      | 3          | 21-51                     | 165                    | 240        | 6.0          | 3.8          | n/a                         | 15        |

Abbreviations: ALT, alanine aminotransferase; CBD, common bile duct; D-Bil, direct bilirubin; GGT, \( \gamma \)-glutamyl transpeptidase; T-Bil, total bilirubin.

\(^a\)CBD stent was placed on day 37 and removed 2 months after the placement.
as the bile salt export pump ABCB11 and multidrug-resistance-associated protein 2 in primary human hepatocyte cell lines,\textsuperscript{20} which impair the secretion of bile acids into the bile ducts. Bile acids were also elevated in our patient. Elevated IL-6 may have contributed to cholestasis and led to hepatobiliary abnormalities in KD.

4 | CONCLUSION

This case of a 4-year-old with dilatation of the CBD in acute KD highlights the usefulness of abdominal ultrasound and the importance of considering dilatation of the CBD as one of the complications of KD. Abdominal ultrasound is not a routine procedure in KD, so it is possible that CBD dilatation in KD may remain latent if not investigated thoroughly. Further prospective studies to support these findings are warranted.

ACKNOWLEDGEMENTS

We would like to thank Editage (https://www.editage.com/) for editing and reviewing this manuscript for English language.

CONFLICT OF INTEREST

None of the authors have any financial or non-financial competing interests to declare in relation to this manuscript.

AUTHOR CONTRIBUTIONS

AM and KI made substantial contributions to the conception or design of the work. AM and TI contributed to the acquisition, analysis, or interpretation of ultrasound findings for the work. KI and MT contributed to the acquisition, analysis, or interpretation of comprehensive data for the work. AM and KI drafted the work and HT revised the work critically for important intellectual content. Final approval of the version to be published was provided by AM, KI, TI, MT, and HT.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

This study was approved by the ethics committee of the University of Tsukuba Hospital. Written informed consent was obtained from the patient’s parents.

CONSENT FOR PUBLICATION

Written informed consent was obtained from the patient’s parents.

ORCID

Kazuo Imagawa https://orcid.org/0000-0002-2512-6043

REFERENCES

1. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a
2. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. *Jpn Allergol.* 1967;16:178-222.

3. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. *Pediatrics.* 1974;54:271-276.

4. Kawasaki T, Singh S. Kawasaki disease - the journey over 50 years: 1967-2017. *Int J Rheum Dis.* 2018;21:7-9.

5. Kobayashi T, Ayusawa M, Suzuki H, et al. Revision of diagnostic guidelines for Kawasaki disease (6th revised edition). *Pediatr Int.* 2020;62(10):1135-1138.

6. Tashiro N, Matsubara T, Uchida M, Katayama K, Ichiyama T, Furukawa S. Ultrasonographic evaluation of cervical lymph nodes in Kawasaki disease. *Pediatrics.* 2002;109:E77-E87.

7. Suddleson EA, Reid B, Woolley MM, Takahashi M. Hydrops of the gallbladder associated with Kawasaki syndrome. *J Pediatr Surg.* 1987;22:956-959.

8. Bader-Meunier B, Hadchouel M, Fabre M, Arnoud MD, Dommergues JP. Intrahepatic bile duct damage in children with Kawasaki disease. *J Pediatr Surg.* 1992;27:750-752.

9. Maurer K, Unsinn KM, Waltner-Romen M, Geiger R, Gassner I. Segmental bowel-wall thickening on abdominal ultrasonography: an additional diagnostic sign in Kawasaki disease. *Pediatr Radiol.* 2008;38:1013-1016.

10. Hamada Y, Ando H, Kamisawa T, et al. Diagnostic criteria for congenital biliary dilatation 2015. *J Hepatobiliary Pancreat Sci.* 2016;23:342-346.

11. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. *Circulation.* 2006;113:2606-2612.

12. Tanoshima R, Hashimoto R, Suzuki T, Ishiguro A, Kobayashi T. Effectiveness of antiplatelet therapy for Kawasaki disease: a systematic review. *Eur J Pediatr.* 2019;178:947-955.

13. Ka K, Maeda K. The Hepatobiliary system in Kawasaki disease (in Japanese). *J Jpn Pediatr Soc.* 1989;93:1852-1859.

14. Petersen C, Mildenberger H, Jablonski M. Painless cholestasis in Kawasaki syndrome-associated with pancreatitis. *Pediatr Surg Int.* 1994;9:118-119.

15. Cherry R, Naon H, Cohen H, Takahashi M, Kaminsky C, Mason W. Common bile duct stenosis and pancreatitis in Kawasaki disease: two cases and a review of the literature. *Pediatr Infect Dis J.* 2010;29:571-573.

16. Mercer S, Carpenter B. Surgical complications of Kawasaki disease. *J Pediatr Surg.* 1981;16:444-448.

17. Edwards KM, Glick AD, Greene HL. Intrahepatic cholangitis associated with mucocutaneous lymph node syndrome. *J Pediatr Gastroenterol Nutr.* 1985;4:140-142.

18. Tremoulet AH, Jain S, Chandrasekar D, Sun X, Sato Y, Burns JC. Evolution of laboratory values in patients with Kawasaki disease. *Pediatr Infect Dis J.* 2011;30:1022-1026.

19. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. *Proc Natl Acad Sci USA.* 1987;84:7251-7255.

20. Diao L, Li N, Brayman TG, Hotz KJ, Lai Y. Regulation of MRP2/ABCC2 and BSEP/ABCB11 expression in sandwich cultured human and rat hepatocytes exposed to inflammatory cytokines TNF-[alpha], IL-6, and IL-1[beta]. *J Biol Chem.* 2010;285:31185-31192.